Physician profile

George Huffmon

Wilmington, NC

NPI 1487626560

$192,040.29

in general payments reported to CMS, 2019-2025

37 companies · $20K in 2025

The $20K reported for 2025 was more than what 99% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$22,925.00
Consulting Fee$8,250.00
Food and Beverage$6,515.83
Travel and Lodging$2,605.33

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic USA, INC. $81,155.38 2019-2020
Medtronic, INC. $61,060.66 2021-2025 Mazor X System, Cd Horizon Spinal System, Anteralign Spinal System With Titan Nanolock Surface Technology
Baylis Medical Company INC $12,160.88 2019-2021
Zimmer Biomet Holdings, INC. $9,552.58 2019-2024 Neuro Plating System
Saluda Medical Americas, INC. $9,376.87 2023-2025 Evoke, Evoke Scs
Nuvasive, INC. $9,242.61 2021-2022
Boston Scientific Corporation $2,737.57 2019-2025 Wavewriter Alpha Prime 16
Southtech Orthopedics $1,320.39 2021
Abbott Laboratories $1,168.87 2019-2025 Proclaim, Eterna, Octrode
Nevro Corp. $785.53 2019-2024 Senza
Baylis Medical Technologies INC. $779.26 2022-2023
Globus Medical, INC. $447.42 2019-2025 Excelsiusgps Robotic Navigation System, Senza
Relievant Medsystems, INC. $423.80 2021-2023 Intracept
Stryker Corporation $248.21 2020-2023 Capri Corpectomy Cage System
Si-Bone, INC. $219.45 2019-2024
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Intrinsic Therapeutics $212.31 2021-2023 Barricaid Acd (Annular Closure Device)
Arthrex, INC. $161.13 2021-2024
Cerapedics INC. $157.31 2022-2024 I-Factor Peptide Enhanced Bone Graft
Providence Medical Technology, INC. $149.44 2021-2025
Aesculap, INC. $104.88 2020-2023 Aesculap, M.Blue
Orthofix Medical, INC. $85.81 2023-2024 Spinal-Stim, Physio-Stim, Cervical-Stim
Ctl Medical Corporation $75.00 2020
Depuy Synthes Sales INC. $62.19 2019-2023 Conduit, Acf
Baxter Healthcare $47.82 2024 Floseal
Medacta USA, INC. $43.46 2024
Arteriocyte Medical Systems, INC. $38.15 2024-2025 Magellan
Ethicon US, LLC $31.59 2023 Stratafix, Dermabond Prineo, Vistaseal
Sanara Medtech INC. $28.16 2024 Celleraterx
Surgalign Spine Technologies, INC. $23.89 2022
Imperative Care, INC $23.83 2022
Biotronik Nro, INC. $22.26 2025 Prospera
Stimwave Technologies Incorporated $20.03 2019
Integra Lifesciences Corporation $16.88 2019
Siemens Medical Solutions USA, INC. $15.41 2021
Pacira Pharmaceuticals Incorporated $14.58 2023 Iovera, Exparel
Kowa Pharmaceuticals America, INC. $14.39 2022
Nalu Medical, INC. $12.29 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

George Huffmon

$192,040.29

in general payments reported 2019-2025

Years
2019-2025
Top company
Medtronic USA, INC.
Context
The $20K reported for 2025 was more than what 99% of providers received nationally.

https://glasscript.com/doctor/66552/george-huffmon

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.